
Assembly Biosciences Investor Relations Material
Latest events

Investor Update
Assembly Biosciences

Q1 2025
8 May, 2025

Q4 2024
20 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Assembly Biosciences Inc
Access all reports
Assembly Biosciences, Inc. is a biopharmaceutical company focused on developing small molecule antiviral therapeutics. It is primarily engaged in the discovery and development of treatments targeting hepatitis B virus (HBV) and hepatitis delta virus (HDV), including a portfolio of HBV core inhibitors and other novel antiviral compounds aimed at managing chronic infections. Additionally, the company explores therapies for herpesviruses, with programs advancing long-acting inhibitors and other non-nucleoside polymerase inhibitors intended for transplant-associated infections and other serious disease conditions. Assembly Biosciences is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ASMB
Country
🇺🇸 United States